2015 Patient Seminar - Chicago, IL, USA

Return to the main Patient Seminar page.

Update on Latest Treatment Opportunities

Cladribine and Rituximab in HCL

Presenter:

BRAF Inhibitors in HCL

Presenter:

Ibrutinib for HCL

Presenter:

Clinical Trials at the NIH

Presenter:

Question & Answer Session

How long does it take for symptoms to appear? (Audio)

Presenters:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

  • Dr. Francesco Forconi, Southampton University Hospital, United Kingdom

When should you start treatment? (Audio)

Presenters:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

  • Dr. James Johnston, Manitoba Institute of Cell Biology, Canada

Is there a difference in outcome from treatment with Cladribine versus Pentostatin? (Audio)

Presenter:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Are there any unique characteristics of patients who do not need treatment right away? (Audio)

Presenters:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

  • Dr. James Johnston, Manitoba Institute of Cell Biology, Canada

Is fever a common reaction to treatment? Are reactions to treatment reduced the 2nd or 3rd time around? (Audio)

Presenters:

  • Dr. Con Tam, Peter MacCallum Cancer Centre, Australia

  • Dr. James Johnston, Manitoba Institute of Cell Biology, Canada

Are there practical ways to help your immune system recover from treatment? (Audio)

Presenters:

  • Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom

  • Dr. Con Tam, Peter MacCallum Cancer Centre, Australia

What is recommended for patients that relapse after shorter than expected remission intervals? (Audio)

Presenters:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Is a bone marrow biopsy recommended after initial treatment? If so, when? (Audio)

Presenters:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

  • Dr. Claire Dearden, The Royal Marsden; Con Tam, M.D., Peter MacCallum Cancer Centre, Australia

  • Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom

Is the profile of patients with HCL changing? (Audio)

Presenter:

  • Dr. Graeme Quest, University of Toronto, Canada

  • Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Are there any risks associated with vaccinations? (Audio)

Presenter:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

What is the relation between HCL and other skin cancers and autoimmune diseases? (Audio)

Presenters:

  • Dr. James Johnston, Manitoba Institute of Cell Biology, Canada

  • Dr. Con Tam, Peter MacCallum Cancer Centre, Australia

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA

Does anyone have experience with long-term management of Cryptococcal Meningitis in HCL patients? (Audio)

Presenter:

  • Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA